SEHK:2157Biotechs
Lepu Biopharma (SEHK:2157): Valuation Check After New GLP-1 CDMO Framework Deal With Lepu Medical
Lepu Biopharma (SEHK:2157) just signed a GLP-1 focused CDMO framework deal with related party Lepu Medical, a move that could turn spare manufacturing capacity into recurring cashflow and reshape how investors think about its pipeline driven story.
See our latest analysis for Lepu Biopharma.
The 1 day share price return of 3.0% to HK$5.76 comes after a volatile few months, with the 3 month share price return still down sharply. However, the year to date share price return and 1 year total...